<DOC>
	<DOCNO>NCT02556762</DOCNO>
	<brief_summary>This randomized phase III trial compare simultaneous modulate accelerated boost standard dose radiotherapy give together chemotherapy treat patient esophageal squamous cell carcinoma .</brief_summary>
	<brief_title>Simultaneous Modulated Accelerated Boost Versus Standard Dose Radiotherapy Esophageal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>Histologic proof primary squamous cell carcinoma esophagus . Primary disease cervical , upper middle thoracic esophagus T14 , N , M0 ( except supraclavicular lymph node ) . Age≥18 &amp; ≤75 . ECOG score 02 . Platelets ≥ 150,000 , Hgb ≥ 10 gm % , ANC ≥ 1500 , serum creatinine ≤ 1.5 mg/dl . Adequate liver function . Patients prior malignancy eligible diseasefree ≥ 5 year . No prior chest radiotherapy , systemic chemotherapy major esophageal surgery . Signed studyspecific inform consent form prior study entry . Patients tracheoesophageal fistula . Patients invasion mucosa trachea major bronchus . Patients uncontrolled serious medical mental illness . Prior RT would result overlap plan RT field . Pregnancy woman childbearing potential men sexually active Women breastfeed baby .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Esophageal cancer</keyword>
	<keyword>Simultaneous modulate accelerated boost</keyword>
	<keyword>Standard dose radiotherapy</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Survival</keyword>
</DOC>